

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16099

Title: Management of hepatitis delta: need for novel therapeutic options

Reviewer's code: 00068251

Reviewer's country: Turkey

Science editor: Jing Yu

Date sent for review: 2014-12-26 16:14

Date reviewed: 2015-01-19 20:55

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear Editor, Word Journal of Gastroenterology 19.01. 2015 Please find below the report for the review titled " Management of hepatitis delta: need for novel therapeutic options" 1. The abbreviation of the "CDH" should be defined in the text at its first occurrence and CDH should be used thereafter. 2. The content of the paragraph which begins as "Myrcludex B was added to (PEG-IFNa) for the first 24 weeks to another 8 patients (B2) while 8 patients are treated with PEG-IFNa alone (B3). 6/7 and 7/7 of patients with data available experienced..... " can be more clearly expressed by using an algorithm, which will be more comprehensible for readers. 3. I have thoroughly checked the paper twice. In terms of grammar, it is OK, however, four sentences (see below) need touch-up work - that is - they need to be restructured and redesigned in order to create a clear-cut statement without any confusion. A-"Treatment with pegylated interferon results in sustained virological response six months post-treatment in one quarter of the patients. B-"These FDA approved molecules include irbesartan, ezetimibe, and ritonavir. Irbesartan, an angiotensin II receptor antagonist used mainly for the treatment of hypertension, ezetimibe, a drug that lowers plasma cholesterol levels, and ritonavir, an antiretroviral drug from the protease inhibitor class used



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

to treat HIV infection". C-"Another drug, cyclosporin A inhibits the binding of HBV preS to NTCP[24] however, its effect on HDV transmission needs further study". D-It is therefore important to study the therapeutic potentials of these drugs, and evolve combined strategies to prevent viral entry, assembly, and transmission as well as induce immune-mediated killing of infected hepatocytes.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16099

Title: Management of hepatitis delta: need for novel therapeutic options

Reviewer's code: 03020543

Reviewer's country: Germany

Science editor: Jing Yu

Date sent for review: 2014-12-26 16:14

Date reviewed: 2015-02-01 21:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors provide an elegant overview on the topic of HBV / HDV coinfection and potential avenues for future treatment options by e. g. targeting the NTCP receptor. The paper could benefit from one or more figures that illustrate the starting points of the respective options. This should be added before publication.